

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR  
15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of June, 2025

**Commission file number: 001-37891**

**AC IMMUNE SA**

(Exact Name of Registrant as Specified in Its Charter)

**EPFL Innovation Park  
Building B  
1015 Lausanne, Switzerland**  
(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

---

On June 19, 2025, AC Immune SA ("AC Immune") held its Annual General Meeting of Shareholders. The final results of the voting on the agenda items are given below. The Management presentation to shareholders is attached hereto as Exhibit 99.1. Prior to the meeting, the board of directors of AC Immune withdrew agenda items 6.1 and 6.2. The final results of the remaining agenda items submitted to a vote of the shareholders are as below and the detailed results will be provided in the minutes which will be published on AC Immune's website (<https://ir.acimmune.com/governance>) within 15 days:

**Annual General Meeting Results**

**Agenda Item 1: 2024 IFRS Consolidated Financial Statements, 2024 Statutory Financial Statements, 2024 Compensation Report**

**Agenda Item 1.1: Approval of 2024 IFRS Consolidated Financial Statements and 2024 Statutory Financial Statements**

AC Immune shareholders approved the 2024 IFRS Consolidated Financial Statements and the 2024 Statutory Financial Statements.

**Agenda Item 1.2: Advisory Vote on the 2024 Compensation Report**

AC Immune shareholders endorsed the 2024 Compensation Report.

**Agenda Item 2: Appropriation of Losses**

AC Immune shareholders approved that the net loss for the year 2024 in the amount of CHF 45,848K increases the "accumulated losses brought forward" of CHF 310,998K, resulting in a new balance of "accumulated losses brought forward" of CHF 356,846K.

**Agenda Item 3: Discharge of the Members of the Board of Directors and the Executive Committee**

AC Immune shareholders approved the discharge of the Members of the Board of Directors and the Executive Committee for the financial year 2024.

**Agenda Item 4: Compensation for the Members of the Board of Directors and the Executive Committee**

**Agenda Item 4.1: Binding vote on Maximum Aggregate Compensation for Members of the Board of Directors from the AGM 2025 to the AGM 2026**

AC Immune shareholders approved the total maximum amount of compensation for the Board of Directors of CHF 1,029K (excluding employer social security contributions) covering the period from the AGM 2025 to the AGM 2026.

**Agenda Item 4.2: Binding vote on Maximum Aggregate Compensation for Members of the Executive Committee for the financial year 2026**

AC Immune shareholders approved the total maximum compensation for the members of the Executive Committee of CHF 7,496K (excluding employer social security contributions) from 1 January 2026 to 31 December 2026.

**Agenda Item 5: Re-elections and Elections**

**Agenda Item 5.1: Re-elections of Members of the Board of Directors**

AC Immune shareholders approved the re-election of Monika Bütler, Carl June, Andrea Pfeifer, and Roy Twyman as Members of the Board of Directors, each until the end of the Annual General Meeting 2026.

---

**Agenda Item 5.2: Elections of Members and Chair of the Board of Directors**

AC Immune shareholders approved the election of Renée Aguiar-Lucander as Member of the Board and of Martin Zügel as Member and Chair of the Board.

**Agenda Item 5.3: Re-election of Members of the Compensation, Nomination and Corporate Governance Committee**

AC Immune shareholders approved the re-election of Monika Bütler and Roy Twyman as Members of the Compensation, Nomination and Corporate Governance Committee, each until the end of the Annual General Meeting 2026.

**Agenda Item 5.4: Election of Member of the Compensation, Nomination and Corporate Governance Committee**

AC Immune shareholders approved the election of Martin Zügel as Member of the Compensation, Nomination and Corporate Governance Committee until the end of the Annual General Meeting 2026.

**Agenda Item 5.5: Re-election of the Statutory Auditors**

AC Immune shareholders approved the re-election of PricewaterhouseCoopers SA, in Lausanne, Switzerland, as AC Immune's statutory auditors for the financial year 2025.

**Agenda Item 5.6: Re-election of the Independent Proxy**

AC Immune shareholders approved the re-election of Reymond & Associés Attorneys, Lausanne, as AC Immune's Independent proxy until the end of the Annual General Meeting 2026.

This Report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3 (File Nos. 333-227016, 333-249655 and 333-277940) and Form S-8 (File Nos. 333-213865, 333-216539 and 333-233019) of AC Immune SA and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**AC IMMUNE SA**

By: /s/ Andrea Pfeifer

Name: Andrea Pfeifer

Title: Chief Executive Officer

By: /s/ Christopher Roberts

Name: Christopher Roberts

Title: Chief Financial Officer

Date: June 20, 2025

---

**EXHIBIT INDEX**

Exhibit Number	Description
<a href="#">99.1</a>	<a href="#">Annual General Meeting Presentation</a>

---



# PIONEERING PRECISION MEDICINE

TARGETED THERAPEUTICS  
FOR NEURODEGENERATIVE DISEASES

## Investor Update

NASDAQ: ACIU | Annual General Meeting – June 19, 2025



## Disclaimer


*This presentation contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.*

*SupraAntigen® is a registered trademark of AC Immune SA in the following territories: AU, CH, EU, GB, JP, RU, SG and USA. Morphomer® is a registered trademark of AC Immune SA in CH, CN, EU, GB, JP, KR, NO and RU.*

## Agenda

1. AC Immune's approach to neurodegenerative diseases
2. Achievements 2024
3. Business strategy and pipeline update
4. Clinical-stage active immunotherapy programs
5. Programs targeting a-syn and NLRP3 inflammasome
6. Key milestones 2025
7. Financial figures
8. Summary and Strategic outlook
9. Agenda items and proposals of the Board of Directors

### 1. AC Immune's approach to neurodegenerative diseases





# AC Immune today – an overview

Pioneering next generation Precision Medicine for neurodegenerative diseases



**Diverse and balanced pipeline** with a large number of wholly-owned assets



**Key differentiation: Precision Medicine**  
Enabled by leadership in Active Immunotherapy



**New breakthroughs**, e.g. morADC<sup>3</sup>: our platforms have repeatedly created potentially transformative innovations



**Partnering**: strategic, risk-mitigating, timely, monetization with >CHF 4 billion in potential milestones



**Cash reserves on Balance sheet**  
Funding into Q1 2027

- Based in Lausanne, Switzerland
- ~170 employees
- Listed September 2016 (NASDAQ: ACIU)
- 100.6 million shares outstanding<sup>1</sup>
- Cash resources of CHF 145.7 million<sup>2</sup>



(1) As of March 31, 2025; excluding treasury shares; (2) As of March 31, 2025; (3) Morphomer-antibody drug conjugate

NASDAQ: ACIU | AGM Presentation, June 2025



© 2025 AC Immune. Not to be used or reproduced without permission

5



## Neurodegenerative diseases

Prevention as the best approach to long-term preservation of neurological health



- AD prevention through combination of advanced diagnosis and early active immunotherapy
- Global disease prevention market potentially over 300 million people

(1) Alzheimer's disease; (2) Gustavsson et al. Alzheimer's and Dement. 2023 19:658-670. <https://doi.org/10.1002/alz.12694>; (3) Monoclonal antibody; (4) Neurodegenerative disease; (5) alpha-synuclein; (6) TAR DNA-binding protein 43; (7) Amyotrophic lateral sclerosis; (8) Limbic-predominant age-related TDP-43 encephalopathy

NASDAQ: ACIU | AGM Presentation, June 2025

© 2025 AC Immune. Not to be used or reproduced without permission

6



## 2. Achievements 2024



### AC Immune 2024 highlights

The foundation for early detection and treatment

#### Clinical-stage active immunotherapies

Targeted active immunotherapies:

- **ACI-24.060<sup>1</sup>** (Takeda)  
Exclusive option and license agreement
- **ACI-35.030<sup>2</sup>** (Janssen J&J)  
Phase 2b trial program, ReTain
- **ACI-7104.056<sup>3</sup>** (wholly-owned)  
Phase 2 trial, VacSYn  
**positive interim safety and immunogenicity**

#### Pipeline and technologies

Biologics, small molecules, combo's

- Wholly-owned assets advanced towards clinical development
- morADC platform unveiled at AAIC with preclinical a-syn<sup>4</sup>/a-syn results
- Small molecule programs targeting a-syn, Tau and NLRP3<sup>5</sup> reaching value inflection points
- Clinical entry of a-syn and TDP-43<sup>6</sup> PET<sup>7</sup> tracers

#### Strong financial position


Operating capital foundation:

- Partner payments in 2024:
  - **ACI-24.060** (Takeda)  
**\$100 million upfront payment**
  - **ACI-35.030** (Janssen J&J)  
**CHF25 million milestone payment**
- Cash runway into 2027

Cash runway permits achievement of key milestones & execution of value-generating innovation

(1) Phase 1b/2; (2) Phase 2b; (3) Phase 2; (4) Alpha-synuclein; (5) (NOD)-like receptor protein 3; (6) TAR DNA-binding protein 43; (7) Positron emission tomography

### 3. Business strategy and pipeline update



#### AC Immune's four core value-driving pillars

Combining biomarker-based clinical development, validated targets and strong collaborations

##### **ACI-35.030 anti-pTau**

The only active immunotherapy in a prevention study for pre-symptomatic Alzheimer's disease

ACTIVE  
Immune Therapy

Janssen  
A Johnson & Johnson Company

##### **ACI-24.060 anti-Abeta**

Biomarker-driven development targeting the hallmark protein in Alzheimer's disease and Alzheimer's in Down syndrome

ACTIVE  
Immune Therapy

Takeda

##### **a-syn-targeted programs for PD**

A unique suite of disease-modifying therapeutics and diagnostics targeting pathological a-syn




##### **NLRP3 inflammasome**


Inhibiting neuroinflammation to alleviate disease pathology and disrupt the negative feedback loop



## Broad and robust pipeline in neurodegenerative diseases

Driven by validated proprietary technology platforms for sustained growth

	Indication	Candidate	Partner	Modality	Discovery	Preclinical	Phase 1	Phase 2	Phase 3
Wholly-owned	Parkinson's disease	ACI-7104.056		anti-a-syn <sup>1</sup> active immunotherapy					
		Morphomer® a-syn		anti-a-syn small molecule					
	Neuro-inflammation	ACI-19764		anti-NLRP3 <sup>2</sup> small molecule inhibitor					
		Anti-NLRP3-ASC <sup>3</sup>		anti-ASC monoclonal antibody					
	ALS <sup>4</sup>	ACI-5891.9		anti-TDP-43 <sup>5</sup> monoclonal antibody					
Partnered	NDDs <sup>6</sup>	morADC		Morphomer-antibody drug conjugate					
	Alzheimer's disease	ACI-24.060		anti-Abeta active immunotherapy	AD <sup>7</sup>	FDA Fast Track			
		ACI-35.030 (JNJ-2056)		anti-pTau active immunotherapy	DS <sup>8</sup>	FDA Fast Track			
		Morphomer Tau		anti-Tau small molecule inhibitor					

 small molecule

(1) alpha-synuclein; (2) (NOD)-like receptor protein 3; (3) Apoptosis-associated speck-like protein containing a CARD, also PYCARD; (4) Amyotrophic lateral sclerosis; (5) TAR DNA-binding protein 43; (6) Neurodegenerative diseases; (7) Alzheimer's disease; (8) Down syndrome

NASDAQ: ACIU | AGM Presentation, June 2025


© 2025 AC Immune. Not to be used or reproduced without permission



11

 AC Immune

## Precision medicine approach enabled by the Morphomer® platform

Developing a suite of tracers against emerging targets in neurodegenerative diseases

	Indication	Candidate	Partner	Modality	Discovery	Preclinical	Phase 1	Phase 2	Phase 3
Wholly-owned	Parkinson's disease	ACI-15916		a-syn <sup>1</sup> -PET <sup>2</sup> tracer (diagnostic)					
	MSA <sup>3</sup>	ACI-12589		a-syn-PET tracer (diagnostic)					
	ALS <sup>4</sup>	ACI-19626		TDP-43 <sup>5</sup> -PET tracer (diagnostic)					
Partnered	Alzheimer's disease	PI-2620		Tau-PET tracer (diagnostic)	FDA Fast Track				



(1) alpha-synuclein; (2) Positron emission tomography; (3) Multiple system atrophy; (4) Amyotrophic lateral sclerosis; (5) TAR DNA-binding protein 43

NASDAQ: ACIU | AGM Presentation, June 2025

© 2025 AC Immune. Not to be used or reproduced without permission



12

 AC Immune



# Technology platforms driving value-creating pharma deals

Strategy: optimize value to risk ratio and retain significant upside

Platform		
Wholly-owned Programs	<ul style="list-style-type: none"><li>■ a-syn active immunotherapy</li><li>■ Anti-TDP-43 mAb<sup>(1)</sup></li><li>■ Anti-NLRP3-ASC mAb</li></ul>	<ul style="list-style-type: none"><li>■ morADC</li><li>■ Mor-a-syn</li><li>■ Mor-TDP-43 PET / Mor-a-syn PET</li><li>■ Mor-NLRP3-ASC</li></ul>

■ Over CHF 400 million in upfront payments from deals; further >CHF 4.3 billion possible

■ Considerable additional potential value in our unpartnered clinical and preclinical programs

(1) Monoclonal antibody

NASDAQ: ACIU | AGM Presentation, June 2025


© 2025 AC Immune. Not to be used or reproduced without permission

13

AC Immune

## 4. Clinical-stage active immunotherapy programs

ACTIVE∞  
Immune Therapy



# Active immunotherapies driving Precision Prevention

Three clinical-stage programs supported by promising data from prior trials

Candidate	Indication	Discovery	Preclinical	Phase 1	Phase 2	Status
ACI-24.060 ( <i>anti-Abeta</i> )	AD <sup>(1)</sup> treatment			FDA Fast Track		Phase 1b/2 ABATE trial ongoing
	AD treatment ( <i>Down syndrome</i> <sup>(2)</sup> )					
ACI-35.030 / JNJ-2056 ( <i>anti-pTau</i> )	AD therapy			FDA Fast Track		Phase 2b ReTain trial ongoing
ACI-7104.056 ( <i>anti-a-syn</i> <sup>(3)</sup> )	PD <sup>(4)</sup> , a-synucleinopathies					Phase 2 VacSYn trial ongoing

**ACI-35.030  
anti-pTau**



**ACI-24.060  
anti-Abeta**



**ACI-7104.056  
anti-a-syn**



(1) Alzheimer's disease; (2) Down syndrome-related Alzheimer's disease; (3) alpha-synuclein; (4) Parkinson's disease

NASDAQ: ACIU | AGM Presentation, June 2025

© 2025 AC Immune. Not to be used or reproduced without permission


15

targeting neurodegenerative diseases

## Major advantages

- ✓ Long-lasting specific immunity for pathological target, consistent, boostable
- ✓ Limited annual dosing (once or twice) after priming year
- ✓ No observed ARIA-E<sup>(1)</sup> to date (safety profile well suited to long-term use)
- ✓ Ease of administration and simple logistics for global access
- ✓ Cost-effective (attractive healthcare economics across global populations)


(1) Amyloid-related imaging abnormalities-edema



16

## Active immunotherapy: a new class of treatment for neurodegenerative disease

Potential for profound social and economic impact




NASDAQ: ACIU | AGM Presentation, June 2025

© 2025 AC Immune. Not to be used or reproduced without permission

17

 AC Immune

### 5. Programs targeting $\alpha$ -syn and NLRP3 inflammasome






# AC Immune's four core value-driving pillars

Combining biomarker-based clinical development, validated targets and strong collaborations



## Pioneering a-syn<sup>1</sup> modalities to address Parkinson's disease

Unique pipeline assets: 3 therapeutics and 2 diagnostics



- Parkinson's disease affects over 6 million people worldwide
- Challenges remain in diagnosis and there are substantial unmet needs for effective therapeutic interventions

(1) alpha-synuclein; (2) Parkinson's disease; (3) Antibody drug conjugate; (4) Positron emission tomography; (5) Investigational New Drug; (6) IND-enabling studies for ACI-15916

## AC Immune's four core value-driving pillars

Combining biomarker-based clinical development, validated targets and strong collaborations

### ACI-35.030 anti-pTau

The only active immunotherapy in a prevention study for pre-symptomatic Alzheimer's disease

### ACI-24.060 anti-Abeta

Biomarker-driven development targeting the hallmark protein in Alzheimer's disease and Alzheimer's in Down syndrome

### a-syn-targeted programs for PD


A unique suite of disease-modifying therapeutics and diagnostics targeting pathological a-syn

### NLRP3 inflammasome

Inhibiting neuroinflammation to alleviate disease pathology and disrupt the negative feedback loop

## NLRP3<sup>1</sup> Inflammasome is a promising therapeutic target

Key disease driver in multiple CNS and other diseases



### AC Immune's unique positioning

- Potential best-in-class compounds
  - Small molecule therapeutics
  - Monoclonal antibody diagnostics
- Multiple substantial indications

#### CNS<sup>10</sup>

- Parkinson's disease
- Alzheimer's disease
- Multiple sclerosis
- Other NDDs<sup>11</sup>

#### Other

- Obesity
- Type 2 diabetes
- Rheumatoid arthritis
- IBD<sup>12</sup>


- Mechanism of action can be applied across a broad range of neuroinflammatory and other diseases

- Pharmacological inhibition of NLRP3 lowers aberrant cytokine release and reduces disease pathology<sup>13,14,15</sup>

(1) Nod-Like Receptor protein containing Pyrin 3; (2) Apoptosis-associated speck-like protein containing a CARD, also called PYCARD; (3) monoclonal antibody; (4) TAR DNA binding protein-43; (5) Venegas *et al.*, 2017; (6) phosphorylated Tau; (7) alpha-synuclein; (8) Interleukin-1 beta; (9) Interleukin-18; (10) Central nervous system; (11) neurodegenerative diseases; (12) Inflammatory bowel disease; (13) Stancu *et al.*, 2019; (14) Dempsey *et al.*, 2018; (15) Gordon *et al.*, 2018



## 6. Key milestones 2025



### Key milestones

Multiple catalysts across pipeline including selected 2025 milestones


● Readouts  
○ Other development events

Active immunotherapies		H1'25	H2'25	
ACI-24.060 (Takeda)	Abeta		●	ABATE Phase 2 trial 12-month treatment completed in AD <sup>1</sup> Dec. 2025
ACI-7104.056	a-syn <sup>2</sup>	●		Phase 2 VacSYn trial in PD <sup>3</sup> : Part 1 interim results, pharmacodynamics, biomarkers
			○	Phase 2 VacSYn trial in PD: Part 2 Initiation <sup>4</sup>
Monoclonal antibodies and small molecule drugs				
Monoclonal antibody	TDP-43 <sup>5</sup>		○	Validated pharmacodynamic assay for clinical readout
Morphomer-NLRP3 (ACI-19764)	NLRP3 <sup>6</sup>	●		Lead candidate declaration and initiation of IND-enabling studies
			○	IND <sup>7</sup> /CTA <sup>8</sup> filing
Morphomer-Tau	Tau		●	Lead candidate declaration and initiation of IND-enabling studies
Morphomer a-syn	a-syn		●	Lead candidate declaration
morADC	Platform (a-syn)	●		<i>In vivo</i> PoC study of proprietary brain delivery platform
Diagnostics				
TDP-43-PET <sup>9</sup> tracer	TDP-43		●	Phase 1 initial readout in genetic FTD <sup>10</sup>
a-syn-PET tracer (ACI-15916)	a-syn		●	Phase 1 readout

(1) Alzheimer's disease; (2) alpha-synuclein; (3) Parkinson's disease; (4) IND/CTA approval; (5) TAR DNA-binding protein 43; (6) (NOD)-like receptor protein; (7) Investigational new drug; (8) Clinical Trial Application; (9) Positron emission tomography; (10) Frontotemporal dementia



## 7. Financial figures



### 2024 Financial Overview

Key financial data (IFRS)

For the year ended December 31,	2024	2023	Change
			(in CHF million) (except per share data)
Revenues	27.3	14.8	12.5
R&D expenses	(62.6)	(54.6)	(8.0)
G&A expenses	(17.3)	(15.3)	(2.0)
Other operating income	0.1	1.5	(1.4)
<b>Total Operating expenses</b>	<b>79.8</b>	<b>68.4</b>	<b>(11.4)</b>
Finance result, net	1.5	(0.6)	2.1
<b>IFRS loss for the period</b>	<b>(51.0)</b>	<b>(54.2)</b>	<b>3.2</b>
IFRS EPS – basic and diluted	(0.51)	(0.64)	0.13

As of December 31,	2024	2023	Change
			(in CHF million)
Cash and cash equivalents	36.3	78.5	(42.2)
Short-term financial assets	129.2	24.6	104.6
<b>Total liquidity<sup>1</sup></b>	<b>165.5</b>	<b>103.0</b>	<b>(62.5)</b>
Total shareholder's equity	112.3	160.6	(48.3)

(1) Liquidity is defined as the cash and cash equivalents plus short-term financial assets. These short-term financial assets are cash held in fixed-term deposits ranging in maturity from 3–12 months

# AC Immune strong Balance Sheet

Operations well-funded into 2027



**Cash of CHF 145.7 million<sup>1</sup>**



**2025 annual cash burn guidance**  
CHF 75m – 85m



**Strong Balance Sheet<sup>2</sup>**  
Cash runway into Q1 2027

Astute  
investment  
strategy focused  
on major value  
drivers and near-  
term catalysts

(1) As of March 31, 2025; (2) Assumes no other milestones or deals included

NASDAQ: ACIU | AGM Presentation, June 2025

© 2025 AC Immune. Not to be used or reproduced without permission

27



## AC Immune strong track record in deals<sup>1</sup> with leading pharma companies

Strategy: optimize value to risk ratio and retain significant upside

Program	Phase	Total value <sup>2</sup>	Upfront <sup>2</sup>	Milestones received <sup>2</sup>	Royalties %	Partner
<b>ACI-24.060</b> (anti-Abeta active immunotherapy)	Phase 1b/2	>USD 2,100	USD 100		Mid-to-high teens	
<b>ACI-35.030</b> (anti-pTau active immunotherapy)	Phase 2b	CHF 500	CHF 26	CHF 20	Low-double digits to mid-teens	
<b>Tau Morphomer®</b> (small molecule drugs)	Phase 1 <sup>6</sup>	CHF 1,860	CHF 80 +USD 50 <sup>7</sup>	CHF 40	Low-double digits to mid-teens	
<b>PI-2620</b> (Tau PET <sup>4</sup> tracer)	Phase 3 <sup>5</sup>	EUR 160	EUR 0.5	EUR 7	Mid-single digits to low-teens	
Other (concluded collaborations)		CHF 121 <sup>3</sup>	CHF 41	CHF 80		
<b>Total (millions)<sup>8</sup></b>		<b>CHF ~4,750</b>	<b>CHF 255.2<sup>9</sup></b>	<b>CHF 147.4</b>		

■ Outstanding potential milestone payments exceed ~CHF 4.3 billion

(1) Disclosure limited due to confidentiality agreements with collaboration partners; (2) In millions; (3) Total payments received from partner until conclusion of agreement; (4) Positron emission tomography; (5) In Alzheimer's disease; (6) Phase 1 completed; (7) Equity investment; (8) Converted to CHF on date of receipt; (9) Excludes convertible note agreement of USD 50 million

NASDAQ: ACIU | AGM Presentation, June 2025







© 2025 AC Immune. Not to be used or reproduced without permission

28



# AC Immune technology platforms driving validating pharma deals

Strategy: optimize value to risk ratio and retain significant upside

Platform	 SupraAntigen®		 Morphomer®	
Program	ACI-24.060	ACI-35.030	Mor Tau	Tau PET
Partner				

■ An integrated approach to Central Nervous System (CNS)-specific therapies


## 8. Summary and Strategic outlook





# Creating the future of Precision Medicine in neurodegeneration

The foundation for early detection and treatment



(1) Phase 1b/2; (2) Phase 2b; (3) Phase 2; (4) Alpha-synuclein; (5) TAR DNA-binding protein 43; (6) Positron emission tomography; (7) (NOD)-like receptor protein 3

NASDAQ: ACIU | AGM Presentation, June 2025

© 2025 AC Immune. Not to be used or reproduced without permission

31



## AC Immune: Pioneering science and precision medicine

Shifting the treatment paradigm for neurodegenerative disease towards precision medicine and disease prevention

NASDAQ: ACIU | AGM Presentation, June 2025


© 2025 AC Immune. Not to be used or reproduced without permission

32





## 9. Agenda items and proposals of the Board of Directors



### Agenda item 1

2024 IFRS Consolidated Financial Statements, 2024 Statutory Financial Statements and 2024 Compensation Report

#### 1.1 Approval of 2024 IFRS Consolidated Financial Statements and 2024 Statutory Financial Statements

- The Board of Directors (Board) proposes that the 2024 IFRS Consolidated Financial Statements and the 2024 Statutory Financial Statements be approved

# Agenda item 1

2024 IFRS Consolidated Financial Statements, 2024 Statutory Financial Statements and 2024 Compensation Report

## 1.2 Advisory vote on the 2024 Compensation Report

- The Board proposes that the 2024 Compensation Report be endorsed (non-binding advisory vote)

# Agenda item 2

Appropriation of Losses

- The Board proposes the following appropriation of losses:

	In CHF K
Accumulated profit (loss) at Jan 1, 2024	(310,998)
Net profit (loss) for the year 2024	(45,848)
Accumulated losses brought forward	(356,846)
Under IFRS accounting standards, the consolidated net loss for the business year 2024 amounted to CHF 50,916K	



## Agenda item 3

### Discharge of the Members of the Board of Directors and the Executive Committee

- The Board proposes that all Members of the Board and of the Executive Committee (EC) be discharged from their liabilities for their activities in the financial year 2024

## Agenda item 4

### Compensation for the Members of the Board of Directors and the Executive Committee

#### 4.1 Binding vote on maximum aggregate compensation for Members of the Board from the AGM 2025 to the AGM 2026

- The Board proposes the approval of the total maximum amount of compensation for the Members of the Board of CHF 1,029,000 (excluding employer social security contributions) covering the period from the AGM 2025 to the AGM 2026.

## Agenda item 4

### Compensation for the Members of the Board of Directors and the Executive Committee

#### 4.2 Binding vote on maximum aggregate compensation for Members of the Executive Committee for the financial year 2026

- The Board proposes the approval of the total maximum amount of compensation for the Members of the EC of CHF 7,496,000 (excluding employer social security) from 1 January 2026 to 31 December 2026.

## Agenda item 5

### Re-elections and Elections

#### 5.1 Re-election of Members of the Board of Directors

- The Board proposes that each of the following persons be re-elected as Member of the Board for a term of office until the end of the AGM 2026:
  - Monika Bütler
  - Carl June
  - Andrea Pfeifer
  - Roy Twyman

## Agenda item 5

### Re-elections and Elections

#### 5.2 Election of Members and the Chair of the Board of Directors

- The Board proposes that each of the following persons be elected for a term of office until the end of the AGM 2026:
  - Renée Aguiar-Lucander as Member of the Board, and
  - Martin Zügel as Member and Chair of the Board

## Agenda item 5

### Re-elections and Elections

#### 5.3 Re-election of Members of the Compensation, Nomination and Corporate Governance Committee

- The Board proposes that:
  - Monika Bütler, and
  - Roy Twyman

be re-elected as Members of the Compensation, Nomination and Corporate Governance Committee for a term of office until the end of the AGM 2026



## Agenda item 5

### Re-elections and Elections

#### 5.4 Election of Member of the Compensation, Nomination and Corporate Governance Committee

- The Board proposes that Martin Zügel be elected as Member of the Compensation, Nomination & Corporate Governance Committee for a term of office until the end of the AGM 2026.

## Agenda item 5

### Re-elections and Elections

#### 5.5 Re-election of the Statutory Auditors

- The Board proposes that PricewaterhouseCoopers SA, in Pully, Switzerland, be re-elected as Statutory Auditors for a term of office for the financial year 2025.

## Agenda item 5

### Re-elections and Elections

#### 5.6 Re-election of the Independent Proxy

- The Board proposes that Reymond & Associés Attorneys in Lausanne, Switzerland be re-elected as Independent Proxy for a term of office until the end of the AGM 2026.

## Agenda item 6

### Changes in the Articles of Association

- The Board of Directors has withdrawn its proposals for agenda items 6.1 and 6.2

We thank you for your attendance  
and your continued support.

